Clinical Trial Search

Primary: Complete Response Rate at the End of Induction — 46 percentage of participants

Primary: Safety and Tolerability — 5; 2; 1; 1 Grade 1/2 event count (no grade 3+)

Primary: Bladder Tumor Recurrence Rate — 41.37 percentage of subjects

Primary: Complete Response (CR) Rate in the Subset of Patients With Carcinoma in Situ (CIS) — 27 percentage of participants

Primary: Disease Recurrence Rate — 27.86; 40 percentage of patients with recurrence — p=0.01

Primary: Number of Participants With Complete Response at 3 Months — 26 Participants

Primary: Complete Response Rate at 3 Months — 39 percentage of participants

Primary: Recurrence Free Survival — 9.6; 16.4 months — p=0.056

Primary: Maximum Tolerated Dose (MTD) — 2 mg/kg Pembrolizumab

Primary: Number of Participants Without Grade ≥ 3 Adverse Event, Graded According to NCI CTCAE Version 4.03 — 15; 14; 20 Participants

Primary: Median Overall Survival — 13.9 months

Primary: Phase I - Dose-limiting Toxicity (DLT) — 0 DLT

Primary: Number of Participants With Recurrence and Recurrence Rate at 1 Year Following Narrow Band Imaging and TURB (Arm A) Versus White Light Trans Urethral Resection of…

Primary: Percentage of Patients With Complete Pathologic Response After 3 Cycles of Treatment — 27.3 percentage of patients

Primary: Number of Participants With Freedom From Progression of Cancer at 4 Months — 20 Participants

Primary: Recurrence Rate at 2 Years — 112; 138; 170; 160 Participants — p=0.1094

Primary: Proportion of Patients With >= 1 Ta or T1 Tumor Detected With Blue Light and Not White Light — 16.4 percentage of participants

Primary: Recurrence Rate at 2 Years — 112; 121; 183; 150 Participants — p=0.1068

Primary: Number of Participants With Grade 3, 4, and 5 Treatment Related Adverse Events — 0; 4; 3; 6 Participants

Primary: Progression-Free Survival (PFS) — 2.8; 5.4; 1.6 months

Primary: Cohort 1: Recurrence-Free Survival (RFS) — NA; 11.60 Months — p==0.0007

Primary: Number of Participants With Progression-free Survival at 6 Months — 3 Participants

Primary: Progression Free Survival (PFS) — 9.5 months

Primary: Progression Free Survival — 8.2 months

Primary: Proportion of Patients With Histologically Confirmed Recurrence Within One 1 Year. — 30.5; 47.3 precentage of participants — p=0.05

Primary: Number of Participants With Adverse Events — 2 Participants

Primary: Percentage of Participants Free From Radical Cystectomy at 3 Years — 88.2 percentage of participants

Primary: Proportion of Patients Receiving Complete Induction Course — 0.833 proportion of patients

Primary: Part 1: Maximum Tolerated Dose or Maximum Deliverable Dose (MDD) — NA; 360 mg

Primary: Evaluate the Efficacy for Treatment of Low/Intermediate- Risk Bladder Tumors, Assessing for the Clinical Response of the Marker Lesion — 13 Participants